Login / Signup

A novel complement C3 inhibitor CP40-KK protects against experimental pulmonary arterial hypertension via an inflammasome NLRP3 associated pathway.

Lei DaiYu ChenJinhua WuZhen HeYueqi ZhangWenjun ZhangYang XieHesong ZengXiaodan Zhong
Published in: Journal of translational medicine (2024)
Our findings suggest that CP40-KK treatment was protective in the MCT-induced rat PAH model, which might serve as a therapeutic option for PAH.
Keyphrases
  • pulmonary arterial hypertension
  • pulmonary artery
  • pulmonary hypertension
  • polycyclic aromatic hydrocarbons
  • high glucose
  • diabetic rats
  • oxidative stress
  • coronary artery
  • endothelial cells
  • nlrp inflammasome